Silence Therapeutics plc (SLNCF)
OTCMKTS · Delayed Price · Currency is USD
1.750
0.00 (0.00%)
Mar 3, 2026, 9:30 AM EST

Silence Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
25.8341.232.321.6616.787.49
Revenue Growth (YoY)
18.13%27.54%49.17%29.01%124.07%2215.11%
Cost of Revenue
2.2410.3413.1313.4610.085.14
Gross Profit
2330.8619.178.196.72.35
Selling, General & Admin
24.1525.526.2725.6827.0519.12
Research & Development
80.0966.8956.0443.5541.5927.63
Other Operating Expenses
1.32-----
Operating Income
-81.18-61.53-63.15-61.04-61.94-49.01
Interest Income
-5.051.84-0.010.18
Interest Expense
--0.09-2.74--0.07-0.44
Other Non-Operating Income (Expense)
1.79--11.39--4.61
Total Non-Operating Income (Expense)
1.794.96-0.911.39-0.06-4.88
Pretax Income
-64.21-56.57-64.04-49.65-62-49.28
Provision for Income Taxes
-0.01-12.34-8.97-0.69-8.71-4.78
Net Income
-64.22-44.22-55.08-50.33-53.28-44.5
Net Income to Common
-64.22-44.22-55.08-50.33-53.28-44.5
Shares Outstanding (Basic)
714637323025
Shares Outstanding (Diluted)
714637323025
Shares Change (YoY)
58.16%24.69%15.21%8.76%19.79%21.55%
EPS (Basic)
-1.35-0.99-1.47-1.56-1.80-1.63
EPS (Diluted)
-1.35-0.99-1.47-1.56-1.80-1.63
Free Cash Flow
-0.11-68.14-50.15-57.227.43-15.43
Free Cash Flow Per Share
-0.00-1.47-1.35-1.78--0.62
Gross Margin
89.06%74.91%59.34%37.83%39.94%31.34%
Operating Margin
-314.27%-149.34%-195.48%-281.87%-369.02%-654.26%
Profit Margin
-297.49%-107.34%-170.51%-232.44%-317.44%-594.03%
FCF Margin
-0.44%-165.38%-155.25%-264.22%44.26%-206.00%
EBITDA
-81.18-60.95-62.51-60.44-61.36-48.33
EBITDA Margin
-314.27%-147.93%-193.52%-279.12%-365.58%-645.21%
EBIT
-81.18-61.53-63.15-61.04-61.94-49.01
EBIT Margin
-314.27%-149.34%-195.48%-281.87%-369.02%-654.26%
Effective Tax Rate
0.02%21.82%14.00%1.39%14.06%9.69%
Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.